MD, UNITED STATES, January 20, 2026 /EINPresswire.com/ -- Future Market Insights (FMI), a leading market intelligence firm, today released its comprehensive analysis of the global lung cancer therapeutics market. The report projects the market to grow from USD 41.8 billion in 2025 to USD 126.5 billion by 2035, achieving a compound annual growth rate (CAGR) of 11.7%. This expansion is fueled by the escalating incidence of lung cancer worldwide, breakthroughs in precision medicine, and the increasing adoption of targeted therapies and immunotherapies. The study, which examines data from 2020 onward, underscores the shift away from traditional chemotherapy toward more effective, personalized treatment options that improve patient outcomes while minimizing side effects.

Lung cancer remains the third most common cancer globally, accounting for 13% of new cases, according to Cancer Research UK. In the United States alone, an estimated 226,650 new cases are projected for 2025, with 110,680 among men and 115,970 among women, as reported by the American Cancer Society. The FMI report highlights how factors such as smoking, environmental pollutants, and genetic predispositions are contributing to this rise, particularly in low- and middle-income countries (LMICs). To address this, pharmaceutical companies are ramping up research and development (R&D) investments in innovative treatments, supported by government policies and expanded insurance coverage for oncology care.

Market Drivers: Rising Incidence and Technological Innovations Fuel Growth

The primary drivers of the lung cancer therapeutics market include the global surge in lung cancer cases and advancements in treatment modalities. Precision medicine, enabled by genomic profiling, has revolutionized care by allowing therapies tailored to specific mutations, such as EGFR and ALK rearrangements in non-small cell lung cancer (NSCLC). Immunotherapies, including checkpoint inhibitors like PD-1/PD-L1 blockers, are gaining traction for their ability to enhance immune responses against cancer cells, often in combination with other regimens.

Data from the report indicates that the market grew from USD 25.4 billion in 2020 to USD 41.8 billion in 2025, reflecting a robust recovery and innovation post-pandemic. Semi-annual projections show a CAGR of 11.7% for the first half (H1) of 2025-2035, slightly dipping to 11.2% in the second half (H2), signaling sustained but maturing demand. Similarly, for 2024-2034, the H1 CAGR stands at 12.6%, with H2 at 12.1%. These figures emphasize the role of emerging technologies, such as AI-driven diagnostics and biomarker analytics, in optimizing treatment sequencing and real-world data applications.

Segmentation Analysis: Targeted Therapies and Injectables Lead the Way

The FMI report segments the market by cancer type, therapy, formulation, molecule type, and distribution channel, providing granular insights into dominant trends.

By cancer type, NSCLC holds the largest share due to its prevalence and the availability of targeted treatments for common mutations. Small cell lung cancer (SCLC) is seeing advancements, including the May 2024 FDA approval of Imdelltra™ (tarlatamab-dlle), the first T-cell engager therapy for extensive-stage SCLC.

In terms of therapy, targeted therapies command 90.5% of the market in 2025, encompassing EGFR inhibitors, tyrosine kinase inhibitors, and KRAS inhibitors. Immunotherapies and angiogenesis inhibitors follow, while cytotoxic chemotherapy, including platinum-based drugs and taxanes, is declining due to higher toxicity.

Regional Insights: Asia Pacific Emerges as Fastest-Growing Market

Geographically, North America leads the lung cancer therapeutics market, benefiting from advanced healthcare infrastructure and early adoption of innovations. However, the Asia Pacific region is poised for the highest growth, with CAGRs exceeding 17% in India and China from 2025-2035, driven by rising prevalence, improving healthcare systems, and increased awareness. South Korea follows at 15.4%, while Germany and Australia show CAGRs of 13.2% and 10.4%, respectively. The United States, with a 6.6% CAGR, reflects a more mature market focused on high-value biologics.

Competitive Landscape: Key Players Innovate Through Approvals and Collaborations

The market is concentrated among Tier 1 companies such as AstraZeneca, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., and Bristol-Myers Squibb, which dominate through product launches and strategic partnerships. Recent developments include the August 2024 FDA approval of Johnson & Johnson's RYBREVANT® combined with LAZCLUZE™ for EGFR-mutated advanced lung cancer, demonstrating superior progression-free survival. Other notables: Dr. Reddy’s Laboratories' March 2024 launch of Versavo (bevacizumab biosimilar) in the UK, and ImmunityBio's April 2024 positive survival data for Anktiva in NSCLC.

Tier 2 players, including Cipla and Hengrui Medicine, are expanding with generics and niche therapies, enhancing affordability.

Request for Sample Report | Customize Report |purchase Full Report -https://www.futuremarketinsights.com/reports/sample/rep-gb-422

Challenges and Opportunities in Lung Cancer Treatment

Despite progress, restraints include limited screening programs—low-dose CT scans are effective but underused—and the side effects of older treatments like fatigue and pneumonitis. Opportunities lie in biosimilars, AI integration for diagnostics, and increased clinical trials, particularly in Asia Pacific where India's pharmaceutical sector and China's innovative launches (e.g., Camrelizumab) are key.

Trends point to a continued emphasis on small and large molecule innovations, with immunotherapy's role expanding in SCLC and combination approaches addressing non-responders.

"This report provides critical insights for stakeholders navigating the evolving landscape of lung cancer care," said an FMI analyst. "As precision medicine advances, the focus on data-driven strategies will be essential for improving survival rates globally."

Explore More Related Studies Published by FMI Research:

About Future Market Insights (FMI)

Future Market Insights, Inc. (FMI) is an ESOMAR-certified, ISO 9001:2015 market research and consulting organization, trusted by Fortune 500 clients and global enterprises. With operations in the U.S., UK, India, and Dubai, FMI provides data-backed insights and strategic intelligence across 30+ industries and 1200 markets worldwide.

Why FMI: Decisions that Change Outcomes- https://www.futuremarketinsights.com/why-fmi

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Have a specific Requirements and Need Assistant on Report Pricing or Limited Budget please contact us - [email protected]

Sudip Saha
Future Market Insights Inc.
+1 347-918-3531
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Information contained on this page is provided by an independent third-party content provider. XPRMedia and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact [email protected]